[TGF beta subtypes in hepatocellular carcinoma].
OBJECTIVE
To detect the expression of three TGF beta isoforms and its clinicopathologic significance in hepatocellular carcinoma(HCC).


METHODS
Surgical specimens of 52 patients with small HCC resection during 1992-1995 were used to determine the immunoreactivity of TGF beta protein by ABC immunohistochemistry. These specimens were divided into recurrence group(G1) and recurrence group(G2) according to whether HCC recurred two years after resection. The relations with recurrence of HCC were analyzed.


RESULTS
The positive rates in G1 and G2 were 85% (17/20) versus 47% (15/32) for TGF beta 1, 90% (18/20) vs. 78% (25/32) for TGF beta 2, and 45% (9/20) vs. 63% (20/32) for TGF beta 3. Significant difference was found in TGF beta 1 and TGF beta 2, but not in TGF beta 3.


CONCLUSIONS
The high immunoreactivity to TGF beta 1 or TGF beta 2 is positively related to the recurrence of HCC.
Pan
Z
Z
Liver Cancer Institute, Zhongshan Hospital, Shanghai Medical University.
Yang
B
B
Liu
Y
Y
D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000378:metabolism*; D005260:Female; D006509:Hepatitis B / Q000150:complications / Q000378:metabolism; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D016212:Transforming Growth Factor beta / Q000378:metabolism*
D016212:Transforming Growth Factor beta